Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study | Zendy

Patricia Murphy | Zendy; Margaret Moline | Zendy; David Mayleben | Zendy; Russell Rosenberg | Zendy; Gary Zammit | Zendy; Kate Pinner | Zendy; Shobha Dhadda | Zendy; Quan Hong | Zendy; Luigi Giorgi | Zendy; Andrew Satlin | Zendy

Open Access

Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study

Author(s) -

Patricia Murphy,

Margaret Moline,

David Mayleben,

Russell Rosenberg,

Gary Zammit,

Kate Pinner,

Shobha Dhadda,

Quan Hong,

Luigi Giorgi,

Andrew Satlin

Publication year - 2017

Publication title -

journal of clinical sleep medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.529

H-Index - 92

eISSN - 1550-9397

pISSN - 1550-9389

DOI - 10.5664/jcsm.6800

Subject(s) - boulevard , library science , medicine , computer science , history , archaeology

To identify dose(s) of lemborexant that maximize insomnia treatment efficacy while minimizing next-morning residual sleepiness and evaluate lemborexant effects on polysomnography (PSG) measures (sleep efficiency [SE], latency to persistent sleep [LPS], and wake after sleep onset [WASO]) at the beginning and end of treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research